Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

Assessment of Serum Level of Interleukin-15 and Interferon Gamma in Alopecia Areata Patients Before and After Baricitinib Treatment

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07645430

Acronym

Alopecia

Enrollment

Registered

2026-06-12

Start date

2023-01-01

Completion date

2026-06-09

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Keywords

Alopecia Areata, Baricitinib, Interleukin-15, Interferon Gamma

Brief summary

The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy. Venous blood samples (5 mL) were collected from each participant at baseline and at six months.

Detailed description

Changes at baseline and immediately after 6 mmonths will be analyzed, primary outcome is the changes in serum levels over 6 months, while secondary outcome is changes in the Severity of Alopecia Tool (SALT score) over 6 months.

Interventions

DRUGBaricitinib 4 MG Oral Tablet

All cases will use oral Baricitinab 4mg daily dose for six months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Adults diagnosed clinically with Alopecia Areata. * Severity of alopecia tool (SALT) score greater than 50. * Only patients with disease duration exceeding six months but less than eight years will be included.

Exclusion criteria

* Patients were excluded if they were pregnant or lactating, and had chronic hepatic or renal disease. * Cases diagnosed with malignancy, scalp infections, or other types of alopecia will also excluded from the current study. * Recent use of systemic treatment within the last 3 months or topical treatment within the last 4 weeks also will be excluded.

Design outcomes

Primary

Measure	Time frame	Description
Serum level of Interleukin-15.	At baseline and immediately after 6 months of follow up.	Measuring the serum level of Interleukin-15 at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.
Serum level of Interferon Gamma.	Baseline and immediately after 6 months of Baricitinab 4mg oral therapy.	Measuring the serum level of Interferon Gamma at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.

Secondary

Measure	Time frame	Description
Changes in the Severity of Alopecia Tool (SALT) score	At Baseline and immediately after 6 months of oral Baricitinab 4mg oral therapy.	Severity of Alopecia Tool (SALT) score is a standardized measurement used by dermatologists to quantify scalp hair loss, ranging from 0 (no hair loss) to 100 (complete baldness). It is calculated by adding the weighted percentages of hair loss from four scalp quadrants: vertex (40%), posterior (24%), right profile (18%), and left profile (18%).

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORAmal Youssif Habashy, MD

Benha University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026